Foxp3+ T regulatory cells (Tregs) are increased in nasal polyps (NP) after treatment with intranasal steroid

The pathogenesis of chronic rhinosinusitis (CRS) with nasal polyps(NP) is still poorly understood. To evaluate the role of Foxp3+ T regulatory cells (Tregs) in the pathogenesis and management of NP, we investigated the location and expression of Foxp3 in NP before and after treatment with intranasal...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 129(2008), 3 vom: 01. Dez., Seite 394-400
1. Verfasser: Li, H B (VerfasserIn)
Weitere Verfasser: Cai, K M, Liu, Z, Xia, J H, Zhang, Y, Xu, R, Xu, G
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2008
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't FOXP3 protein, human Forkhead Transcription Factors Glucocorticoids Pregnadienediols RNA, Messenger Mometasone Furoate 04201GDN4R Interleukin-10 130068-27-8
LEADER 01000naa a22002652 4500
001 NLM182446697
003 DE-627
005 20231223162908.0
007 cr uuu---uuuuu
008 231223s2008 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2008.07.031  |2 doi 
028 5 2 |a pubmed24n0608.xml 
035 |a (DE-627)NLM182446697 
035 |a (NLM)18793874 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Li, H B  |e verfasserin  |4 aut 
245 1 0 |a Foxp3+ T regulatory cells (Tregs) are increased in nasal polyps (NP) after treatment with intranasal steroid 
264 1 |c 2008 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 04.12.2008 
500 |a Date Revised 19.11.2015 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a The pathogenesis of chronic rhinosinusitis (CRS) with nasal polyps(NP) is still poorly understood. To evaluate the role of Foxp3+ T regulatory cells (Tregs) in the pathogenesis and management of NP, we investigated the location and expression of Foxp3 in NP before and after treatment with intranasal steroid. NP specimens were obtained from 14 patients with NP before and after intranasal administration of mometasone (50 microg/day for 4 weeks). Foxp3 was detected by double immunofluorescence stain, quantitative reverse transcriptase polymerase chain reaction (RT-PCR), flow cytometry and western blot. The concentration of interleukin(IL)-10 in supernatants of homogenized tissue was measured by enzyme-linked immunosorbent assay (ELISA). We found that Foxp3 and IL-10 were downregulated in NP compared to the control mucosa (P<0.05). Foxp3 and IL-10 expression were increased significantly after intranasal steroid treatment (P<0.05). And Foxp3 was tightly correlated with IL-10 in NP (P<0.05) after treatment. These data suggest that Foxp3 is downregulated in NP and intranasal steroid attenuates the chronic inflammatory response by enhancing the expression and function of Foxp3 in NP 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a FOXP3 protein, human  |2 NLM 
650 7 |a Forkhead Transcription Factors  |2 NLM 
650 7 |a Glucocorticoids  |2 NLM 
650 7 |a Pregnadienediols  |2 NLM 
650 7 |a RNA, Messenger  |2 NLM 
650 7 |a Mometasone Furoate  |2 NLM 
650 7 |a 04201GDN4R  |2 NLM 
650 7 |a Interleukin-10  |2 NLM 
650 7 |a 130068-27-8  |2 NLM 
700 1 |a Cai, K M  |e verfasserin  |4 aut 
700 1 |a Liu, Z  |e verfasserin  |4 aut 
700 1 |a Xia, J H  |e verfasserin  |4 aut 
700 1 |a Zhang, Y  |e verfasserin  |4 aut 
700 1 |a Xu, R  |e verfasserin  |4 aut 
700 1 |a Xu, G  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 129(2008), 3 vom: 01. Dez., Seite 394-400  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:129  |g year:2008  |g number:3  |g day:01  |g month:12  |g pages:394-400 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2008.07.031  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 129  |j 2008  |e 3  |b 01  |c 12  |h 394-400